- Cellmid licensees have made significant progress commercialising lung and bladder cancer tests using midkine
- Quest validates lung cancer diagnostic test on the Luminex commercial platform
- Pacific Edge Ltd gains CLIA registration for US commercial lab.
SYDNEY, Tuesday, 26 March 2013: Cellmid Limited (ASX:CDY) provides the following market update on two cancer diagnostic tests using the company’s proprietary midkine technology under license. The Company is pleased to advise that both of its licensees have achieved significant milestones in their product development and commercialisation programs.
Lung Cancer License - Quest (Celera)
Cellmid signed a license agreement with Quest (Celera) in October 2009 enabling Quest to include midkine as one of the biomarkers in lung cancer tests. The license covers using midkine for the early diagnosis, prognosis, disease monitoring and management of lung cancer. The terms of the agreement provide for a milestone payment at the time of regulatory clearance for the lung cancer test, and royalties to be paid semi-annually.
For further information please download PDF below:
